| |
|
|
|
Xtalks, Online
2024-02-07
Join this webinar to learn how to mitigate risk in viral vector manufacturing with tailored solutions and a flexible approach. Discover how unique and transferable technical capabilities in multiple viral vector types can significantly accelerate a development path and future-proof gene therapy products.
The featured experts will walk the attendees through the customer journey at Oxford Biomedica from client onboarding to the successful manufacture of adeno-associated virus (AAV) and lentiviral vectors. They will share success stories of optimized production processes and successful transfer into good manufacturing practice (GMP). Attendees will also hear about end-to-end automation of analytical assays and computer-aided biology strategies to enhance the development, bioprocessing and characterization of viral vectors for gene therapies.
A live Q&A session will follow the presentation, offering attendees a chance to pose questions to the team of experts.
Join this webinar to learn about successful case studies in viral vector manufacturing that use tailored solutions and a flexible approach.
Keywords: Gene Therapy, Drug Development, AAV, Viral Vector, Viral Vector Manufacturing, Cell & Gene Therapies, AAV Manufacturing, CDMO/CMO
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Amy Barker, PhD, Principal Scientist, Process Development, Oxford Biomedica
Andre Raposo, PhD, Director, Innovation Department, Oxford Biomedica
Hannah Boss, Director, Head of Quality Control, Oxford Biomedica
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-02-07
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|